Recursion Pharmaceuticals has raised $60 million to step up its artificial intelligence-enabled drug discovery activities. The series B equips Recursion to move beyond its initial focus on repurposing ...

Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning. The round was led by ...

Recursion Pharmaceuticals Inc., a biotech company leveraging artificial intelligence to discover new therapies, has raised a $60 million series B financing led by the Silicon Valley-based venture firm ...

Announcing an artificial intelligence (AI) drug discovery partnership with Nvidia earlier this month, Recursion co-founder and CEO Chris Gibson, PhD, spoke as much about dollars as he did about drugs ...

Recursion Pharmaceuticals LLC has raised $12.9 million in Series A financing on the promise that it can convert drugs idling on pharmaceutical companies’ shelves into therapies for rare diseases. is ...